{"id":56951,"date":"2024-11-06T08:05:46","date_gmt":"2024-11-06T08:05:46","guid":{"rendered":"https:\/?p=56951"},"modified":"2024-11-06T08:05:46","modified_gmt":"2024-11-06T08:05:46","slug":"exact-sciences-q3-financial-analysis","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/exact-sciences-q3-financial-analysis\/","title":{"rendered":"Exact Sciences Q3 Financial Analysis: Key Earnings and Investor Insights"},"content":{"rendered":"

Exact Sciences Corporation (EXAS)<\/a> reported robust financial and operational performance in its third-quarter 2024 earnings. With record revenue, improved EBITDA, and significant pipeline advancements, the company demonstrated growth despite minor net losses.<\/p>\n

Key developments include FDA approval for the Cologuard Plus\u2122 test and notable data on its blood-based colorectal cancer screening test, positioning Exact Sciences as a continued innovator in the diagnostics space.<\/p>\n

Before we dive in, we have a special offer! For a limited time, you can get 70% off Stock Target Advisor\u2019s premium features. Claim your discount<\/a> here!<\/p>\n

\"Promotion<\/a><\/p>\n

Key Insights from Exact Sciences’ Earnings Report:<\/h2>\n

In the third quarter, Exact Sciences achieved a total revenue of $709 million, marking a 13% year-over-year increase. Screening revenue, largely from Cologuard tests, contributed $545 million, while Precision Oncology added $164 million.<\/p>\n

Despite a net loss of $38 million, the company saw a substantial 42% increase in adjusted EBITDA, reaching $99 million. Exact Sciences also delivered a free cash flow of $113 million and improved its adjusted EBITDA margin by 500 basis points, reflecting stronger operational efficiency.<\/p>\n

Is now the time to buy Exact Sciences? Access our full analysis report here<\/a>, it\u2019s free.<\/p>\n

The company reached significant milestones in its pipeline with the FDA approval of the Cologuard Plus\u2122 test, enhancing sensitivity while reducing false positives by over 30%. It also presented promising data for a blood-based colorectal cancer screening test, showcasing 88% sensitivity for colorectal cancer, and its first peer-reviewed publication on the Oncodetect\u2122 test for monitoring residual disease has been accepted.<\/p>\n

\"\"<\/a><\/p>\n

Positive Implications for Investors:<\/h2>\n

For investors, the third quarter indicates promising growth in revenue and operational strength. The FDA approval of Cologuard Plus\u2122 suggests a potential for increased screening adoption, especially with Medicare coverage anticipated in 2025. The company’s financial position, with $1.02 billion in cash and investments, supports further expansion, bolstered by Exact Sciences\u2019 ExactNexus\u2122 technology platform, which enhances patient engagement and streamlines the testing process.<\/p>\n

Stay ahead in the market\u2014explore Stock Target Advisor’s Top-Rated stocks<\/a> and make informed investment choices!<\/p>\n

Negative Implications for Investors:<\/h2>\n

However, Exact Sciences remains highly leveraged, with debt-to-equity metrics in the lower half of its sector. This financial structure may introduce additional risk, particularly as the company seeks further growth.<\/p>\n

Additionally, although revenue growth is strong, the company\u2019s net loss and modestly reduced 2024 revenue guidance may concern investors. The updated forecast reflects slightly lower full-year revenue, reduced from $2.81\u2013$2.85 billion to $2.73\u2013$2.75 billion, signaling potential headwinds in sustaining the current pace of growth.<\/p>\n

Curious about Exact Sciences’ performance in ETFs<\/a>? Dive into Stock Target Advisor’s comprehensive analysis for the latest trends and projections.<\/p>\n

Stock Target Advisor\u2019s Analysis on Exact Sciences:<\/h2>\n

Stock Target Advisor<\/a> provides a neutral outlook on Exact Sciences, highlighting both strong and weak indicators. The analysis incorporates five positive signals, such as high market capitalization, superior revenue growth, and positive cash flows, with six negative signals, including high leverage, a high price-to-book ratio, and lower-than-average dividend growth.<\/p>\n

The average target price by analysts for the stock is $78.16, with recent ratings from Canaccord Genuity, TD Cowen, and Jefferies set between $75 and $95.<\/p>\n

Ready to take your investments to the next level? For a limited time, get 70% off on Stock Target Advisor. Get started here!<\/a><\/p>\n

Conclusion:<\/h2>\n

Exact Sciences\u2019 third-quarter performance underscores its strong market position in cancer diagnostics, backed by growth in revenue, cash flow, and product advancements.<\/p>\n

With consistent growth in its core screening and oncology revenue, Exact Sciences appears well-positioned to expand its influence in the diagnostics sector, balancing near-term risks with substantial opportunities for growth.<\/p>\n","protected":false},"excerpt":{"rendered":"

Exact Sciences Corporation (EXAS) reported robust financial and operational performance in its third-quarter 2024 earnings. With record revenue, improved EBITDA, and significant pipeline advancements, the…<\/p>\n","protected":false},"author":17,"featured_media":34385,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-56951","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"acf":[],"yoast_head":"\nExact Sciences Q3 Financial Analysis: Key Earnings and Investor Insights<\/title>\n<meta name=\"description\" content=\"Explore Exact Sciences\u2019 Q3 2024 earnings, including record revenue, Cologuard Plus FDA approval, and improved cash flow.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/exact-sciences-q3-financial-analysis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exact Sciences Q3 Financial Analysis: Key Earnings and Investor Insights\" \/>\n<meta property=\"og:description\" content=\"Explore Exact Sciences\u2019 Q3 2024 earnings, including record revenue, Cologuard Plus FDA approval, and improved cash flow.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/exact-sciences-q3-financial-analysis\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-06T08:05:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2023\/05\/STA-Frame-19.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Muzzammil Ahmad\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@https:\/\/x.com\/Muzzammil625\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Muzzammil Ahmad\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/exact-sciences-q3-financial-analysis\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/exact-sciences-q3-financial-analysis\/\"},\"author\":{\"name\":\"Muzzammil Ahmad\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\"},\"headline\":\"Exact Sciences Q3 Financial Analysis: Key Earnings and Investor Insights\",\"datePublished\":\"2024-11-06T08:05:46+00:00\",\"dateModified\":\"2024-11-06T08:05:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/exact-sciences-q3-financial-analysis\/\"},\"wordCount\":582,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News & Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/exact-sciences-q3-financial-analysis\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/exact-sciences-q3-financial-analysis\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/exact-sciences-q3-financial-analysis\/\",\"name\":\"Exact Sciences Q3 Financial Analysis: Key Earnings and Investor Insights\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2024-11-06T08:05:46+00:00\",\"dateModified\":\"2024-11-06T08:05:46+00:00\",\"description\":\"Explore Exact Sciences\u2019 Q3 2024 earnings, including record revenue, Cologuard Plus FDA approval, and improved cash flow.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/exact-sciences-q3-financial-analysis\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/exact-sciences-q3-financial-analysis\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/exact-sciences-q3-financial-analysis\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exact Sciences Q3 Financial Analysis: Key Earnings and Investor Insights\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\",\"name\":\"Muzzammil Ahmad\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"caption\":\"Muzzammil Ahmad\"},\"description\":\"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/\",\"https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625\"],\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Exact Sciences Q3 Financial Analysis: Key Earnings and Investor Insights","description":"Explore Exact Sciences\u2019 Q3 2024 earnings, including record revenue, Cologuard Plus FDA approval, and improved cash flow.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/exact-sciences-q3-financial-analysis\/","og_locale":"en_US","og_type":"article","og_title":"Exact Sciences Q3 Financial Analysis: Key Earnings and Investor Insights","og_description":"Explore Exact Sciences\u2019 Q3 2024 earnings, including record revenue, Cologuard Plus FDA approval, and improved cash flow.","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/exact-sciences-q3-financial-analysis\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2024-11-06T08:05:46+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2023\/05\/STA-Frame-19.png","type":"image\/png"}],"author":"Muzzammil Ahmad","twitter_card":"summary_large_image","twitter_creator":"@https:\/\/x.com\/Muzzammil625","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"Muzzammil Ahmad","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/exact-sciences-q3-financial-analysis\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/exact-sciences-q3-financial-analysis\/"},"author":{"name":"Muzzammil Ahmad","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8"},"headline":"Exact Sciences Q3 Financial Analysis: Key Earnings and Investor Insights","datePublished":"2024-11-06T08:05:46+00:00","dateModified":"2024-11-06T08:05:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/exact-sciences-q3-financial-analysis\/"},"wordCount":582,"commentCount":0,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News & Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/exact-sciences-q3-financial-analysis\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/exact-sciences-q3-financial-analysis\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/exact-sciences-q3-financial-analysis\/","name":"Exact Sciences Q3 Financial Analysis: Key Earnings and Investor Insights","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2024-11-06T08:05:46+00:00","dateModified":"2024-11-06T08:05:46+00:00","description":"Explore Exact Sciences\u2019 Q3 2024 earnings, including record revenue, Cologuard Plus FDA approval, and improved cash flow.","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/exact-sciences-q3-financial-analysis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/exact-sciences-q3-financial-analysis\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/exact-sciences-q3-financial-analysis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Exact Sciences Q3 Financial Analysis: Key Earnings and Investor Insights"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8","name":"Muzzammil Ahmad","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","caption":"Muzzammil Ahmad"},"description":"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.","sameAs":["https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/","https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625"],"url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/56951","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=56951"}],"version-history":[{"count":1,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/56951\/revisions"}],"predecessor-version":[{"id":56956,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/56951\/revisions\/56956"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/34385"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=56951"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=56951"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=56951"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}